Telik Announces Second Quarter 2011 Financial Results
PALO ALTO, Calif., Aug. 11, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today reported a net loss of $3.0 million, or $0.06 per share, for the second quarter ended June 30, 2011, compared with a net loss of $4.9 million, or $0.09 per share, for the comparable period in 2010.
For the quarter ended June 30, 2011, total operating costs and expenses were $3.0 million, compared with $5.0 million in the 2010 second quarter. Operating expenses in the 2011 second quarter included stock-based compensation expense of approximately $0.4 million. Operating expenses were approximately 40% lower in the second quarter of 2011 compared with the same period in 2010, primarily due to lower headcount and related costs, lower clinical development expenses and lower facility costs.
For the six months ended June 30, 2011, Telik reported a net loss of $6.7 million, or $0.12 per share, compared with a net loss of $10.3 million, or $0.19 per share, for the six months ended June 30, 2010. Total operating expenses for the first six months of 2011 were $6.7 million, compared with $10.4 million for the first six months of 2010. Operating expenses in the first six months of 2011 included approximately $0.7 million in stock-based compensation expense. The reduction in operating expenses of approximately 36% in the first six months of 2011 compared with the same period in 2010 was primarily due to lower headcount and related expenses, lower clinical development and lower facility expenses.
At June 30, 2011, Telik had $17.1 million in cash, cash equivalents and investments including restricted investments, compared to $24.1 million at December 31, 2010.
Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The company's most advanced drug candidate is Telintra®, a modified glutathione analog intended for the treatment of hematologic disorders including myelodysplastic syndrome; followed by Telcyta®, a cancer activated prodrug for the treatment of a variety of cancers. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at www.telik.com.
TELIK, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.
Statements of Operations
(In thousands, except per share amounts)
Three Months Ended
Six Months Ended
Operating costs and expenses:
Research and development
General and administrative
Total operating costs and expenses
Loss from operations
Interest and other income (expense), net
Basic and diluted net loss per share
Weighted average shares used to calculate basic
and diluted net loss per share
Selected Balance Sheet Data
Cash, cash equivalents, investments and restricted investments
SOURCE Telik, Inc.